Literature DB >> 9769117

In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells.

C Kim1, M Matsumura, K Saijo, T Ohno.   

Abstract

HLA-A2402-restricted and carcinoembryonic-antigen(CEA)-specific cytotoxic T lymphocytes (CTL) were induced by culturing human peripheral blood mononuclear cells (PBMC) on formalin-fixed autologous adhesive PBMC that had been loaded with CEA-bound latex beads. The CTL killed the CEA-producing HLA-type matched cancer cells, but not the non-producers of CEA, at an effector/target ratio of 10 within 24 h. On the basis of available HLA-A24-binding peptides, we have also attempted to identify the epitope peptide recognized by the CTL. The peptide CEA652(9), TYACFVSNL, stimulated the CTL most strongly when pulsed on HLA-A2402-expressing target cells. The other nine peptides so far tested were also active, but less efficient in their effect on CTL. The CTL failed to kill target cells pulsed with the HLA-A2-binding CEA peptide, CAP-1. The CTL were also generated on the fixed adherent cells previously pulsed with the peptide CEA652(9). Cytotoxic activity of the CTL was inhibited by monoclonal antibodies against CD3, CD8, and MHC class I molecules. These results suggest that human autologous CTL will be inducible on the autologous fixed PBMC without use of the cultured target cancer cells if tumor antigenic protein is available.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9769117     DOI: 10.1007/s002620050508

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Tumor vaccine against recurrence of hepatocellular carcinoma.

Authors:  Bao-Gang Peng; Li-Jiang Liang; Qiang He; Ming Kuang; Jia-Ming Lia; Ming-De Lu; Jie-Fu Huang
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

3.  Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs.

Authors:  Shunroh Ohtsukasa; Satoshi Okabe; Hironori Yamashita; Takehisa Iwai; Kenichi Sugihara
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-15       Impact factor: 4.553

4.  HLA-DRB1 allele polymorphisms in genetic susceptibility to esophageal carcinoma.

Authors:  Jun Lin; Chang-Sheng Deng; Jie Sun; Xian-Gong Zheng; Xing Huang; Yan Zhou; Ping Xiong; Ya-Ping Wang
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

5.  Suppression of postsurgical recurrence of hepatocellular carcinoma treated with autologous formalin-fixed tumor vaccine, with special reference to glypican-3.

Authors:  Issei Kawashima; Yuri Kawashima; Yasuo Matsuoka; Kiyotaka Fujise; Hideki Sakai; Mari Takahashi; Toshiaki Yoshikawa; Tetsuya Nakatsura; Takeshi Ishihara; Tadao Ohno
Journal:  Clin Case Rep       Date:  2015-04-17

6.  Autologous fixed tumor vaccine: a formulation with cytokine-microparticles for protective immunity against recurrence of human hepatocellular carcinoma.

Authors:  Bao Gang Peng; Shu Qin Liu; Ming Kuang; Qiang He; Saeri Totsuka; Lan Huang; Jiefu Huang; Ming-De Lu; Li-Jiang Liang; Kam W Leong; Tadao Ohno
Journal:  Jpn J Cancer Res       Date:  2002-04

7.  Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT.

Authors:  Hideki Harada; Kaoru Saijo; Satoru Watanabe; Koji Tsuboi; Tadao Nose; Isamu Ishiwata; Tadao Ohno
Journal:  Jpn J Cancer Res       Date:  2002-03

8.  Recurrent peritoneal serous carcinoma that was unmanageable with paclitaxel-carboplatin therapy responded to autologous formalin-fixed tumor vaccine.

Authors:  Jui-Tung Chen; Tadao Ohno
Journal:  Clin Case Rep       Date:  2015-09-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.